ArticleFrontiers in cellular and infection microbiology2026
Development of an indirect enzyme-linked immunosorbent assay based on the nucleocapsid protein of bovine parainfluenza virus type 3.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Establishment and Application of an Indirect ELISA for Detecting Getah Virus IgG Antibodies in Swine Based on the E2EP3 Peptide.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Bovine parainfluenza virus type 3 (BPIV3) is an important pathogen in the bovine respiratory disease complex. The purpose of this study was to develop an efficient and rapid serological detection method, an indirect enzyme-linked immunosorbent assay (iELISA), for BPIV3. Methods: The full-length N gene of BPIV3 was amplified from reverse-transcribed BPIV3 cDNA and ligated into the pET-28a prokaryotic expression vector. The recombinant target N protein was correctly expressed. After purification, the target N protein was used to immunize BALB/c mice to prepare polyclonal antibodies. After experimental optimization, an iELISA for detecting antibodies against the BPIV3 N protein was established using purified protein and prepared polyclonal antibodies. Results: The recombinant N protein was efficiently expressed after induction with isopropyl β-D-1-thiogalactopyranoside at 32°C for 16 h. Immunization of BALB/c mice with the purified recombinant N protein elicited polyclonal antibodies that specifically reacted with BPIV3, with an antibody titer of 1:256000. The optimized iELISA conditions were as follows. Microtiter plates were coated with antigen at 5× 10 Conclusion: The N protein polyclonal antibody prepared in this study provides an important biological basis for research on the mechanism of BPIV3 infection. The establishment of an iELISA can enable the rapid screening of clinical samples, thereby providing reliable technical support for the epidemiological investigation of BPIV3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.